News

Eli Lilly says GLP-1 pill for diabetes and weight loss effective in study, plans to seek FDA approval
Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...
The Score: UnitedHealth, Netflix, Eli Lilly and More Stocks That Defined the Week
Pharmaceutical companies—including Eli Lilly and Novo Nordisk, which currently dominate the obesity market—have been testing ...
Daily Pill May Work as Well as Ozempic for Weight Loss and Blood Sugar
Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable ...
Why Eli Lilly and Company (LLY) Is Among the Best Blue Chip Stocks to Buy According to Billionaires
We recently published a list of 15 Best Blue Chip Stocks to Buy According to Billionaires. In this article, we are going to ...
Eli Lilly: Cementing Its GLP-1 Empire With Orforglipron's Promising Phase 3 Results
Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...
Where Will Eli Lilly Be in 5 Years?
Continue » The leader in diabetes and obesity Despite Lilly's huge success in treating diabetes and obesity, it's not the ...
UnitedHealth tumbles, Eli Lilly climbs, TSMC holds outlook
On today's Market Minute, Madison Mills takes a closer look at the top stories on Wall Street. UnitedHealth Group (UNH) stock ...
Eli Lilly: Still Great, But Still Too Expensive Even As Earnings Near
Eli Lilly benefits from rising cash flow and a strong pipeline, yet elevated pricing versus peers limits near-term gains. See ...